Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 known ✓ | P03952 | 1/20 | 0.38 |
| ▸ | CA2 known ✓ | P00918 | 2/20 | 0.36 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | RORC | P51449 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | WNT3A | P56704 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 5/20 | 0.40 |
| ▸ | CDK1 | P06493 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12551052 | 0.98 | KDM4E (0.54) | KDM4EALDH1A1RORCMEN1KMT2A | |
| SCHEMBL12551054 | 0.84 | KDM4E (0.51) | KDM4EALDH1A1RORCMEN1KMT2A | |
| SCHEMBL12551046 | 0.81 | KDM4E (0.49) | KDM4EALDH1A1RORCMEN1KMT2A | |
| SCHEMBL12294725 | 0.80 | HRH3 (0.48) | KDM4EALDH1A1KMT2AMAPTGAA | |
| SCHEMBL12551048 | 0.80 | KDM4E (0.47) | KDM4EALDH1A1RORCMEN1KMT2A | |
| SCHEMBL10066949 | 0.80 | ALDH1A1 (0.57) | KDM4EALDH1A1RORCMEN1KMT2A | |
| SCHEMBL12551056 | 0.79 | KDM4E (0.46) | KDM4EALDH1A1RORCMEN1KMT2A | |
| SCHEMBL24858705 | 0.77 | KDM4E (0.51) | KDM4EALDH1A1RORCMEN1KMT2A | |
| SCHEMBL19245039 | 0.77 | KDM4E (0.51) | KDM4EALDH1A1RORCMEN1KMT2A | |
| SCHEMBL27603139 | 0.77 | HRH3 (0.41) | KDM4EALDH1A1MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12605486-B2 | Afibrotic compounds, devices, and uses thereof | SIGILON THERAPEUTICS, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-20250235409-A1 | IMPLANTABLE PARTICLES AND RELATED METHODS | SIGILON THERAPEUTICS, INC. | 2025-07-24 | — | — | US | disclosed |
| US-12161760-B2 | Implantable particles and related methods | SIGILON THERAPEUTICS, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| US-20230123802-A1 | COMPOSITIONS, DEVICES, AND METHODS FOR FACTOR VII THERAPY | SIGILON THERAPEUTICS, INC. | 2023-04-20 | — | — | US | disclosed |
| US-20220267794-A1 | COMPOSITIONS, DEVICES, AND METHODS FOR TREATING FABRY DISEASE | SIGILON THERAPEUTICS, INC. | 2022-08-25 | — | — | US | disclosed |
| EP-3946463-A1 | COMPOSITIONS, DEVICES AND METHODS FOR FACTOR VII THERAPY | Sigilon Therapeutics, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| US-20210145889-A1 | METHODS, COMPOSITIONS, AND IMPLANTABLE ELEMENTS COMPRISING STEM CELLS | SIGILON THERAPEUTICS, INC. | 2021-05-20 | — | — | US | disclosed |
| US-20210145759-A1 | IMPLANTABLE PARTICLES AND RELATED METHODS | SIGILON THERAPEUTICS, INC. | 2021-05-20 | — | — | US | disclosed |
| US-20210060205-A1 | AFIBROTIC COMPOUNDS, DEVICES, AND USES THEREOF | SIGILON THERAPEUTICS, INC. | 2021-03-04 | — | — | US | disclosed |
| EP-3773517-A1 | IMPLANTABLE PARTICLES AND RELATED METHODS | Sigilon Therapeutics, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| CN-112203646-A | Implantable particles and related methods | 西吉隆医疗股份有限公司 | 2021-01-08 | — | — | CN | disclosed |
| EP-3759101-A1 | AFIBROTIC COMPOUNDS, DEVICES, AND USES THEREOF | Sigilon Therapeutics, Inc. (US) | 2021-01-06 | — | — | EP | disclosed |
| CN-112105612-A | Anti-fibrotic compounds, devices and uses thereof | 西吉隆医疗股份有限公司 | 2020-12-18 | — | — | CN | disclosed |
| US-20200263196-A1 | METHODS, COMPOSITIONS, AND IMPLANTABLE ELEMENTS COMPRISING ACTIVE CELLS | SIGILON THERAPEUTICS, INC. | 2020-08-20 | — | — | US | disclosed |
| EP-3687580-A1 | METHODS, COMPOSITIONS, AND IMPLANTABLE ELEMENTS COMPRISING ACTIVE CELLS | Sigilon Therapeutics, Inc. (US) | 2020-08-05 | — | — | EP | disclosed |
| WO-2019195056-A1 | METHODS, COMPOSITIONS, AND IMPLANTABLE ELEMENTS COMPRISING STEM CELLS | SIGILON THERAPEUTICS, INC. (US) | 2019-10-10 | — | — | WO | disclosed |
| WO-2019195055-A1 | IMPLANTABLE PARTICLES AND RELATED METHODS | SIGILON THERAPEUTICS, INC. (US) | 2019-10-10 | — | — | WO | disclosed |
| WO-2019067766-A1 | METHODS, COMPOSITIONS, AND IMPLANTABLE ELEMENTS COMPRISING ACTIVE CELLS | SIGILON THERAPEUTICS, INC. (US) | 2019-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220267794-A1 | COMPOSITIONS, DEVICES, AND METHODS FOR TREATING FABRY DISEASE | GLA, GAA, GBA1 | KLKB1 536/4885CA2 1255/4885GAA 2/4885 |
| US-20210145759-A1 | IMPLANTABLE PARTICLES AND RELATED METHODS | TNNT2, TNNI3, TNNC1 | KLKB1 1284/4885CA2 3003/4885GAA 331/4885 |
| US-12161760-B2 | Implantable particles and related methods | TNNT2, TNNI3, TNNC1 | KLKB1 1284/4885CA2 3003/4885GAA 331/4885 |
| US-20210060205-A1 | AFIBROTIC COMPOUNDS, DEVICES, AND USES THEREOF | TGFB2, TGFB1, COL2A1 | KLKB1 1959/4885CA2 1100/4885GAA 399/4885 |
| US-20210145889-A1 | METHODS, COMPOSITIONS, AND IMPLANTABLE ELEMENTS COMPRISING STEM CELLS | MSI2, CXCL12, SOST | KLKB1 3146/4885CA2 2526/4885GAA 1306/4885 |
| US-20250235409-A1 | IMPLANTABLE PARTICLES AND RELATED METHODS | TNNT2, TNNI3, TNNC1 | KLKB1 1284/4885CA2 3003/4885GAA 331/4885 |
| US-20230123802-A1 | COMPOSITIONS, DEVICES, AND METHODS FOR FACTOR VII THERAPY | F7, F13B, F9 | KLKB1 165/4885CA2 3309/4885GAA 960/4885 |
| US-12605486-B2 | Afibrotic compounds, devices, and uses thereof | SLC11A2, ARG1, COL2A1 | KLKB1 2126/4885CA2 243/4885GAA 1868/4885 |
| US-20200263196-A1 | METHODS, COMPOSITIONS, AND IMPLANTABLE ELEMENTS COMPRISING ACTIVE CELLS | ALDH1A2, MYOC, PDE6C | KLKB1 1568/4885CA2 541/4885GAA 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.